Opthea (ASX:OPT) outlines clinical data of OPT-302 at ARVO 2022

• Retinal biopharmaceutical company Opthea (OPT) presented its clinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
• The presentation was titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy”
• The ARVO poster presented results of an analysis of subjects with Polypoidal Choroidal Vasculopathy enrolled in the Phase 2b randomised, sham-controlled study of patients with treatment naïve exudative AMD
• OPT-302 achieved superior visual acuity gains and anatomic improvements when used in combination with ranibizumab
• Opthea shares remain steady at $1.01 as of 11:54 am AEST

Retinal biopharmaceutical company Opthea (OPT) presented its clinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

The presentation titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy” was held on May 1 and appeared in a session on clinical and translational research and AMD therapies excluding anti-VEGF.

The ARVO poster presented results of an analysis of subjects with Polypoidal Choroidal Vasculopathy (PCV type CNV) enrolled in the Phase 2b randomised, sham-controlled study of patients with treatment naïve exudative AMD.

In this study, subjects received either monotherapy with ranibizumab (Lucentis) or combination therapy with ranibizumab and one of two doses of OPT-302.

Of the 366 participants, 66 were identified as having PCV lesions at baseline based on multimodal imaging analysis of color fundus photography, fluorescein angiography and SD-OCT.

“We have received positive feedback on the potential utility of OPT-302 combination therapy for patients with PCV lesions and we look forward to evaluating additional data which is being obtained from the ongoing OPT-302 Phase 3 ShORe and COAST trials which are expected to enroll a significant number of treatment naïve patients with PCV,” CEO Dr Megan Baldwin said.

OPT-302 achieved superior visual acuity gains and anatomic improvements when used in combination with ranibizumab, compared to monthly ranibizumab monotherapy in these subjects with PCV type CNV.

Opthea shares remain steady at $1.01 as of 11:54 am AEST.